ABBISKO-B(02256): Hu Yu Pharmaceutical announced the latest clinical progress of ipatasertib and pimertinib at the ESMO Annual Meeting.

ABBISKO-B (02256) released an announcement that its subsidiary Shanghai Hengyu Biomedical Technology Co., Ltd. (Hengyu Biomedical) announced at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting the latest clinical data on the safety and efficacy of its self-developed small molecule FGFR4 inhibitor, ipatigotinib (ABSK011), in Phase I clinical trials targeting advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression. The data released showed that the ipatigotinib 220mg twice daily (BID) group demonstrated excellent efficacy in FGF19 overexpression aHCC patients treated with immune checkpoint inhibitors (ICIs) and multi-targeted small molecule tyrosine kinase inhibitors (mTKIs), with an overall response rate (ORR) of 44.8%, a median duration of response (mDoR) of 7.4 months, and a median progression-free survival (mPFS) of 5.5 months. In addition, the Phase II clinical trial design of the small molecule CSF-1R inhibitor pimetonib (ABSK021) in combination with chemotherapy with or without trastuzumab as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC) will also be presented at this conference.